Drugs / Autologous Tolerogenic Dendritic Cells
Autologous Tolerogenic Dendritic Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06852625 | May 2025 → Mar 2028 expected | transplant rejection | Fundacion Clinic per a la Recerca Biomédica | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05207995 | Mar 2022 → Dec 2023 | diabetes mellitus | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous tolerogenic dendritic cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05207995 ↗ |
| Known as | ATDC | “Autologous Tolerogenic Dendritic Cells (D+1 to D+3 post-transplantation), ATDC, 1 million ATDC/Kg over a period of 30 minutes (up to 1 hour) will administer between Day 1 and...” NCT06852625 ↗ |
| Known as | MSC-tolDC | “Autologous tolerogenic dendritic cells treated with Vitamin-D3, co-cultivated with mesenchymal stem cell and primed peptides (MSC-tolDC) injected subcutaneous.” NCT05207995 ↗ |
| Modality | Cell therapy | “autologous monocyte-derived dendritic cells tolerised with Vitamin-D3” NCT05207995 ↗ |
| Route | Subcutaneous | “injected subcutaneous” NCT05207995 ↗ |